Detection of CYP3A4 Activity in Human Hepatic Organoids by LC-MS

Human hepatic organoids provide a long-term, genetically stable, and well-characterized model system that can recapitulate key hepatic functions and pathophysiology of diseases, as well as provide functional readouts, including CYP3A4 activity, albumin secretion, and urea production. Below, we describe a protocol for assessing cytochrome P450 (CYP) enzymatic activity in human hepatic organoids using liquid chromatography-mass spectrometry (LC-MS) for drug testing.

Materials

  • Biosafety cabinet
  • Pipet-aid
  • Pipettes and tips (P1000, P200, P20, P10, P2)
  • For harvesting organoids:
    • 5 mL serological pipettes
    • 15 mL conical tubes
    • 1.5 mL tubes
    • Gentle Cell Dissociation Reagent (GCDR) (Catalog #100-0485)
  • Tube racks
  • Styrofoam box with ice
  • See More
    • 37°C water bath
    • 24-well plate of healthy hepatic organoid cultures in HepatiCult™ Organoid Growth Medium (Human) (Catalog #100-0385) or HepatiCult™ Organoid Differentiation Medium (Human) (Catalog #100-0383)
    • Reagents for CYP reaction and mass spectrometry:
      • Acetonitrile
      • Substrates (e.g. midazolam, tolbutamide, dextromethorphan)
      • Metabolites for standard curve generation
      • CYP reaction buffer (e.g. Krebs-Henseleit Buffer, Hank’s Balanced Salt Solution, culture media)
      • Quench solution (acetonitrile + 0.1% formic acid)
    See Less

For information regarding the culture and passaging of human liver organoids using HepatiCult™, refer to the Technical Manual (Document #10000008300).


Protocol

(Optional) Harvest hepatic organoids from Matrigel® domes if required (Day 8 - 13 of differentiation):

  1. Gently aspirate culture medium.
    Note: Multiple domes per sample may be required to yield an appropriate amount of material for mass spectrometry analysis from the harvesting step. It is recommended to harvest 6 domes of differentiated organoids in HepatiCult™ Organoid Differentiation Medium (ODM) from a 24-well plate.
  2. Add 1 mL of room temperature GCDR to each well of a 24-well plate. You can use this addition to gently detach the domes off the plate.
  3. Aspirate detached domes and GCDR with a P1000 pipette and transfer to a 15 mL conical tube.
  4. Wash each well with 1 mL GCDR to collect any remaining organoids and add them to the tube.
  5. Pipet up and down five times with a 5 mL serological pipet to disrupt the Matrigel® domes and release the organoids.
  6. Incubate on ice for 5 minutes.
  7. Centrifuge at 300 x g for 5 minutes.
  8. Aspirate the supernatant.
    Note: A Matrigel® cushion may be observed on top of the pellet when pooling multiple domes. This should also be carefully aspirated.
  9. Gently resuspend the organoids in 1 mL CYP reaction buffer by flicking the tube and swirling with a pipette tip.
    Note: CYP reactions can be performed in a buffer or culture medium.
  10. Centrifuge at 300 x g for 5 minutes.
  11. Aspirate the supernatant.
  12. Resuspend the organoids in a final volume of 450 ÎĽL CYP reaction buffer and transfer to a 1.5 mL tube.
    Note: Proliferative organoids in HepatiCult™ Organoid Growth Medium (Human) (OGM) tend to fragment during harvest from Matrigel®. However, the fragments still display CYP activity in a donor-specific manner.

Cytochrome P450 Reaction:

  1. Prepare CYP substrates at 1,000X final concentration in acetonitrile.
    Note: 1X substrate reaction concentration recommendations are listed in Table 1.
  2. Dilute CYP substrates to 10X in the CYP reaction buffer.
  3. Prepare a 1.5 mL tube with 450 ÎĽL CYP reaction buffer without organoids as a negative control.
  4. Pre-warm organoids in CYP reaction buffer at 37°C for 5 minutes.
    Note: If using organoids without recovery from Matrigel® domes, carefully remove the culture medium and replace it with 450 μL CYP reaction buffer before returning to the incubator to pre-warm.
  5. Add 50 μL of 10X CYP substrates to each organoid sample and negative control, and return to 37°C.
  6. Collect 50 ÎĽL samples of supernatant at desired time points.
  7. Immediately terminate the reactions by adding 50 ÎĽLof ice-cold quench solution.
    Note: If a different volume of supernatant is collected, add an equal volume of ice-cold quench solution.
  8. Vortex samples vigorously.
  9. Store samples in airtight vials at -80°C until analysis by LC-MS.

Table 1. Substrate Reaction Concentration Recommendations

CYP Substrate Metabolite 1X Substrate Reaction Concentration
CYP3A4 Midazolam OH-Midazolam 10 ÎĽM
CYP2C9 Tolbutamide OH-Tolbutamide 100 ÎĽM
CYP2D6 Dextromethorphan Dextrorphan 100 ÎĽM

LC-MS Sample Preparation:

  1. Thaw samples on ice.
  2. Centrifuge at ≥ 3,000 x g for 10 minutes at 4°C.
  3. Transfer supernatant to mass spectrometry vial or sample plate.
  4. Perform analysis.


Bar graph demonstrating the detection of CYP3A4 enzymatic activity through LC-MS

Figure 1. Detection of CYP3A4 Activity in Human Hepatic Organoids by LC-MS

Quantification of CYP3A4 enzymatic activity in hepatic organoids differentiated in HepatiCult™ ODM for 13 days through LC-MS, measuring the accumulation of 1'-hydroxy midazolam following exposure to midazolam over 24 hours. N = 1 donor, mean values from 2 experiments. Error bars = SD.

Bar graph demonstrating the levels of metabolites as a product of CYP activity in two different human hepatic organoid lines.

Figure 2. Hepatic Organoids Differentiated in HepatiCult™ ODM Exhibit Activity of Various CYP Enzymes

The activity of three different CYP enzymes can be detected in hepatic organoids by LC-MS through measurement of accumulated metabolite following exposure to known substrates. CYP substrates were added to harvested organoids for 24 hours on Day 14 of culture in HepatiCult™ ODM, before collecting supernatant for analysis. OH-Mid = OH-Midazolam; OH-Tol = OH-Tolbutamide; Dextro = Dextrorphan. N = 2 organoid lines. Error bars = SD.

Panel A is a schematic of a workflow involving human hepatic organoid culture in HepatiCult™ OGM and HepatiCult™ ODM and LC-MS analysis CYP enzymatic activity in organoids for drug testing. Panel B demonstrates induction of CYP3A4 activity in differentiated human hepatic organoids upon calcitriol treatment as measured through LC-MS analysis of CYP3A4 metabolite levels.

Figure 3. Induction of CYP3A4 Activity in Hepatic Organoids Can Be Detected by LC-MS

Hepatic organoid fragments are seeded in HepatiCult™ OGM for 5 days for growth and expansion before differentiation in HepatiCult™ ODM. Between days 8 and 13 of differentiation, organoids can be treated with test compounds for functional analysis and toxicology studies. CYP3A4 enzymatic activity in hepatic organoids can be modulated by drug treatment. Upon addition of calcitriol (Day 13) to hepatic organoid cultures in HepatiCult™ ODM, midazolam metabolism increased compared to baseline levels as detected by LC-MS for 1’-hydroxy midazolam. N = 1 donor, mean values from 2 experiments. Error bars = SD.

  • Document #PR00090
  • Version 1.0.0
  • July 2024


  • Explore These Resources